1733 — Apex Biotechnology Income Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedSmall CapNeutral

Annual income statement for Apex Biotechnology, fiscal year end - December 31st, TWD millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	2,005	2,132	2,244	1,677	1,852
Cost of Revenue
Gross Profit	452	572	577	531	521
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	1,902	1,927	2,093	1,553	1,724
Operating Profit	103	205	152	124	128
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	111	185	200	141	153
Provision for Income Taxes
Net Income After Taxes	94.6	202	181	116	128
Minority Interest
Net Income Before Extraordinary Items
Net Income	94.8	202	182	116	128
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	98.7	204	182	116	128
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.873	1.93	2.03	1.3	1.27
Dividends per Share